Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 18/20 | 0.51 |
| ▸ | HTR2B | P41595 | 18/20 | 0.51 |
| ▸ | HTR2A | P28223 | 9/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337382 | 1.00 | HTR2C (0.51) | HTR2CHTR2BHTR2A | |
| SCHEMBL337619 | 1.00 | HTR2C (0.51) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL14816152 | 0.98 | HTR2C (0.50) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL23124413 | 0.98 | HTR2C (0.50) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL9940935 | 0.98 | HTR2C (0.50) | HTR2CHTR2BHTR2A | |
| SCHEMBL981281 | 0.89 | HTR2C (0.45) | HTR2CHTR2BHTR2A | |
| SCHEMBL21209411 | 0.89 | HTR2C (0.45) | HTR2CHTR2BHTR2A | |
| SCHEMBL21193054 | 0.89 | HTR2C (0.45) | HTR2CHTR2BHTR2A | |
| SCHEMBL15799573 | 0.89 | HTR2C (0.49) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL3760136 | 0.87 | HTR2C (0.44) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025061029-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2025-03-27 | — | — | WO | claimed |
| CN-115413278-B | Pyrimidine derivative and composition for preventing or treating neurodegenerative disease and cancer comprising same | 丸仁制药株式会社 | 2025-01-10 | — | — | CN | claimed |
| CN-115151534-B | Inhibitors of interleukin-1 receptor associated kinase (IRAK)/FMS-like receptor tyrosine kinase (FLT 3), pharmaceutical products thereof and methods of use thereof | 南京药石科技股份有限公司 | 2024-02-06 | — | — | CN | claimed |
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-12-12 | — | — | US | claimed |
| EP-3897832-B1 | N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE | NOVARTIS AG (CH) | 2023-10-11 | — | — | EP | claimed |
| CN-110382499-B | FGFR inhibitor and application thereof | 贝达药业股份有限公司 | 2023-01-03 | — | — | CN | claimed |
| CN-115413278-A | Novel pyrimidine derivative and composition for preventing or treating neurodegenerative disease and cancer comprising same | 丸仁制药株式会社 | 2022-11-29 | — | — | CN | claimed |
| CN-115151534-A | Inhibitors of interleukin-1 receptor-related kinase (IRAK)/FMS-like receptor tyrosine kinase (FLT 3), pharmaceutical products thereof, and methods thereof | 南京药石科技股份有限公司 | 2022-10-04 | — | — | CN | claimed |
| US-RE47689-E1 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2019-11-05 | — | — | US | claimed |
| EP-2809322-B9 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2019-10-30 | — | — | EP | claimed |
| EP-2809322-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2019-05-15 | — | — | EP | claimed |
| US-9617268-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-04-11 | — | — | US | claimed |
| EP-4747234-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | Muna Therapeutics ApS (DK) | 2026-05-27 | — | — | EP | disclosed |
| US-12595265-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2026-04-07 | — | — | US | disclosed |
| US-12577226-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12559462-B2 | Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20020049212-A1 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER PRODUCTS INC. | 2002-04-25 | — | — | US | disclosed |
| US-20020040031-A1 | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system | NEO THERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| US-20020040032-A1 | Methods for stimulation of synthesis of synaptophysin in the central nervous system | NEOTHERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| EP-1122257-A1 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER INC. (US) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | GABRA5, GABRA2, GABRB2 | HTR2C 358/4885HTR2B 332/4885HTR2A 479/4885 |
| US-20020049212-A1 | Benzimidazole compounds as ORL1-receptor agonists | OPRL1, ORMDL3, OGFRL1 | HTR2C 507/4885HTR2B 992/4885HTR2A 1581/4885 |
| US-20020040032-A1 | Methods for stimulation of synthesis of synaptophysin in the central nervous system | GAP43, BDNF, APP | HTR2C 688/4885HTR2B 305/4885HTR2A 378/4885 |
| US-12559462-B2 | Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | HTR2C, HTR1A, HTR2A | HTR2C 1/4885HTR2B 10/4885HTR2A 3/4885 |
| US-12577226-B2 | Compounds for treating Huntington's disease | HTT, HYPK, GRIN2C | HTR2C 31/4885HTR2B 95/4885HTR2A 113/4885 |
| US-12595265-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVRL1, ACVR2A | HTR2C 612/4885HTR2B 1962/4885HTR2A 1757/4885 |
| US-20020040031-A1 | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system | APP, BACE1, SARNP | HTR2C 3054/4885HTR2B 1110/4885HTR2A 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.